Table 3

Family history of cancer and risk of glioma: risks estimated by standardized incidence ratios (SIRs) and odds ratios (ORs)

Family history of canceraCases N (%)Controls N (%)SIR gliomabSIR glioma/SIR controlsOR (95% CI)c,d
(n = 468)(n = 768)
Lip, oral cavity, pharynx6 (1.3)10 (1.3)0.5 (0.2–1.0)0.90.9 (0.3–2.6)
Stomach17 (3.6)13 (1.7)1.4 (0.8–2.2)1.92.2 (1.0–4.6)
Colon37 (7.9)40 (5.1)1.1 (0.8–1.4)1.41.4 (0.9–2.2)
Lung33 (7.1)56 (7.3)0.7 (0.5–1.0)1.01.0 (0.6–1.6)
Bone7 (1.5)8 (1.0)6.0 (2.4–12.4)1.41.1 (0.3–2.7)
Melanoma5 (1.1)6 (0.8)0.5 (0.2–1.2)1.41.3 (0.4–4.5)
Nonmelanoma
Skin6 (1.3)8 (1.0)ee1.3 (0.4–3.9)
Breast38 (8.1)54 (7.0)0.7 (0.5–0.9)1.11.2 (0.8–1.9)
Cervix5 (1.1)5 (0.7)0.7 (0.2–1.5)1.51.5 (0.4–6.2)
Endometrial/uterine not otherwise specified6 (1.3)12 (1.6)0.4 (0.2–1.0)0.70.8 (0.3–2.4)
Ovary8 (1.7)16 (2.1)0.9 (0.4–1.7)0.70.8 (0.3–2.0)
Prostate24 (5.1)20 (2.6)0.9 (0.6–1.3)1.82.1 (1.1–3.8)
Bladder6 (1.3)7 (0.9)0.3 (0.1–0.7)1.11.4 (0.4–4.0)
Non-Hodgkin’s disease
Lymphoma11 (2.4)17 (2.2)0.9 (0.5–1.6)1.00.8 (0.4–1.8)
Hodgkin’s disease10 (2.1)7 (0.9)2.3 (1.1–4.2)2.32.4 (0.9–6.3)
Leukemia9 (1.9)17 (2.2)0.9 (0.4–1.6)0.90.7 (0.3–1.7)
Any malignancy200 (42.7)281 (36.6)0.7 (0.6–0.8)1.11.2 (0.9–1.6)
  • a Only cancers reported by at least five cases and five controls are included in the analysis, or sites that were a priori of interest because of previous findings.

  • b Glioma only, no controls.

  • c The reference group for each odds ratio estimate was comprised of study participants without a family history of the cancer of interest and can be obtained by subtracting from the total of 468 cases and 768 controls.

  • d All odds ratio estimates were adjusted for age at interview (continuous), race (white, nonwhite), sex, study hospital, and proximity of residence to hospital (<15 miles, ≥15 miles).

  • e Standardized incidence ratios were not calculated because the expected numbers of nonmelanoma skin cancers was not available from the Connecticut Tumor Registry.